Skip to main content
SpringerLink
Log in

Who took the tech out of biotech?

  • Commentary
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

In recent years biotech executives have felt pressure from their investors and handlers to tone down talk of the firm's new technology because it sends the message that the company isn't sufficiently product focused. This is rubbish!

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Author notes

  1. Elizabeth Silverman is a veteran biotech equities analyst who now advises and consults to biotech companies. She is at 11 Riverside Drive 14HW, New York, New York 10023, USA. elizsil@aol.com

Authors
  1. Elizabeth Silverman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silverman, E. Who took the tech out of biotech?. Nat Biotechnol 24, 255–256 (2006). https://doi.org/10.1038/nbt0306-255

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0306-255

  • Springer Nature America, Inc.

Search

Navigation